Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs

This study demonstrated the concept of developing potent novel multivalent antitoxins against all BoNTs or other toxins, using the RBD of these toxins as an alternative antigen to inactivated toxins. KEY POINTS: • Antitoxins based on the receptor-binding domains of botulinum neurotoxins were made. • Novel antitoxin binds RBD; traditional antitoxin mainly binds light chain or HN domain. • A tetravalent antitoxin could prevent and treat the four mixed neurotoxins in vivo.PMID:37058230 | DOI:10.1007/s00253-023-12515-2
Source: Applied Microbiology and Biotechnology - Category: Microbiology Authors: Source Type: research